about
Human immunoglobulin allotypes: possible implications for immunogenicityConsensus protein designBulk production of the antiviral lectin griffithsinEarly implementation of QbD in biopharmaceutical development: a practical exampleCrystal structure of TNFα complexed with a poxvirus MHC-related TNF binding proteinBiopharmaceuticals from microorganisms: from production to purificationCharacterizing biological products and assessing comparability following manufacturing changes.The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studiesBiosimilars of biological drug therapies: regulatory, clinical and commercial considerations.Evolution of highly active enzymes by homology-independent recombination.Screening for peptide drugs from the natural repertoire of biodiverse protein folds.Optimization algorithms for functional deimmunization of therapeutic proteins.Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia.Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a miceThe immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsIn vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.Monoclonal antibody humanness score and its applications.Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytesProtein therapeutics--lessons learned and a view of the future.Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.COBEpro: a novel system for predicting continuous B-cell epitopesNative-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a micesNebula, a network-based algorithm to predict binding between human leukocyte antigens and peptidesEngineering tissue alternatives to animals: applying tissue engineering to basic research and safety testing.Are biosimilars really generics?Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIIIEngineering the variable region of therapeutic IgG antibodies.Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics.Organophosphorus hydrolase as an in vivo catalytic nerve agent bioscavenger.Targeting malignant mitochondria with therapeutic peptides.Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study.A snapshot of biologic drug development: Challenges and opportunities.Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.HLA class I binding prediction via convolutional neural networks.Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives.
P2860
Q24651893-232A5161-E276-439E-9771-78E048AD981BQ26748100-0E0EBEF0-E525-46C9-912B-3CBAA2D3C99AQ26801491-96A7A1CD-0F7A-400D-A65C-FC82FF1024F4Q26830466-5AA17ADB-C04C-4C24-9D60-DF481DF786E5Q27657836-A6A7B3FB-AA21-4B93-ABE4-EE0B99F338BFQ28066997-2264CFB4-C45F-4D06-9EA2-9A74E789BE46Q30344134-37519C5E-59C0-4305-A86D-D8381726A26AQ30401825-E61481BB-DD6A-4BC4-B544-95E4E800696DQ30406304-9292BBAF-9628-456A-806B-27DB104B1B71Q30793113-B9DF5080-54AF-4CAA-919B-DBD05F59405BQ33233385-C151849C-3ADF-4649-8686-0E6D1C404E9EQ33551448-CDE9AD86-72E2-49F2-952E-D2C993D3CE87Q33767727-5F70E0D9-5316-4206-BF9A-F3C0E605F830Q33934165-DCA94FCC-F7A4-4566-8114-C3DFDAF3646DQ33954639-BE93EEDF-CC73-4DEF-BF26-62CA0273A379Q34110768-A40CC8ED-3A23-41B9-97F4-04B0E4E8E795Q34678914-8E4174EF-1FD3-43E6-B85C-BCB44F99473BQ34688731-2C22E3C8-69B3-4DE6-BDA0-8F27774E0C9EQ34798313-8EDED754-9EE5-4BBE-B901-385932CDF96CQ34804520-5AC2351B-782C-473C-A379-1128F74D5B55Q35498838-AB05D07C-E167-43E2-9A65-6956EF7450CDQ35829158-7F8EF226-7EAA-4F38-986A-6646AADF7049Q36349537-4563CA6A-DAB6-42AB-827A-9E02A1CD933BQ36970547-65B20BD7-8E4A-47DF-A2CD-063884B74AE2Q37101584-A4571C3F-F33F-4AFD-AB3F-023FDD5FFF97Q37174443-49A21EC2-6FE2-439B-B908-E8284A601911Q37202382-BFF3D005-0BF9-42C4-83B1-15027D87ADC7Q37542225-FE6AA825-7514-4BB5-B4F7-1B9534C52CC1Q37690328-75C36072-929A-4048-B00B-189B612EE377Q37718280-133D12DC-61AF-42AA-A81B-D73338EC81E9Q37853324-3B827CA7-6251-487D-BB72-7646066C7F2DQ37864339-E7A56F78-89A8-4316-8DAD-770EE6280CB8Q37989116-34158C87-5990-40B9-A124-EDDE372F31C6Q38040407-602271B7-5A90-492B-9ED1-C0BEA9ED7013Q38628086-E767B8FA-67B3-440D-9B35-5D2209F043FCQ38651271-564F409C-6AFC-497F-9388-6FD550D83A93Q38795816-8674DBAA-8989-4E20-B05B-BEBFDC23187BQ38811689-916C49D5-18A5-48A4-8AAF-E34C4AF2FD75Q38819387-798609D1-174B-41E0-92B3-C1EFC904E40FQ39855054-1DB4B0B9-F681-438E-986B-B35A7143031C
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Minimizing the immunogenicity of protein therapeutics.
@ast
Minimizing the immunogenicity of protein therapeutics.
@en
type
label
Minimizing the immunogenicity of protein therapeutics.
@ast
Minimizing the immunogenicity of protein therapeutics.
@en
prefLabel
Minimizing the immunogenicity of protein therapeutics.
@ast
Minimizing the immunogenicity of protein therapeutics.
@en
P2093
P1433
P1476
Minimizing the immunogenicity of protein therapeutics.
@en
P2093
Arthur J Chirino
Marie L Ary
Shannon A Marshall
P356
10.1016/S1359-6446(03)02953-2
P577
2004-01-01T00:00:00Z